Compare TCPC & LAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TCPC | LAB |
|---|---|---|
| Founded | 2006 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 280.2M | 326.2M |
| IPO Year | 2006 | 2008 |
| Metric | TCPC | LAB |
|---|---|---|
| Price | $3.25 | $0.78 |
| Analyst Decision | Sell | Hold |
| Analyst Count | 2 | 1 |
| Target Price | ★ $3.50 | $1.35 |
| AVG Volume (30 Days) | 654.0K | ★ 2.8M |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | ★ 18.23% | N/A |
| EPS Growth | N/A | ★ 61.54 |
| EPS | N/A | ★ 0.33 |
| Revenue | N/A | ★ $101,937,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $2.63 |
| P/E Ratio | ★ N/A | $2.35 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.08 | $0.70 |
| 52 Week High | $7.41 | $1.72 |
| Indicator | TCPC | LAB |
|---|---|---|
| Relative Strength Index (RSI) | 45.39 | 42.42 |
| Support Level | $3.10 | $0.70 |
| Resistance Level | $3.54 | $1.01 |
| Average True Range (ATR) | 0.10 | 0.07 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 51.92 | 9.64 |
BlackRock TCP Capital Corp is an externally-managed specialty finance company focused on middle-market lending. Its investment objective is to achieve high total returns through current income and capital appreciation, with an emphasis on principal protection. It seeks to achieve its investment objective through investments in debt securities of middle-market companies. The group generates returns through a combination of the receipt of contractual interest payments on debt investments and origination and similar fees, and, to a lesser extent, equity appreciation through options, warrants, conversion rights, or direct equity investments.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. The company operates in one segment. Its technology includes: Genomics; Single-cell proteomics; Spatial proteomics. Its platforms include: Biomark X9 System, CyTOF XT system, and Hyperion XTi Imaging System. The company offers a diverse range of instrumentation, consumables, and services that generate high-quality data across early discovery, translational and clinical research. Geographically, it operates in Americas; EMEA and Asia-Pacific.